These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37318043)

  • 1. Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions.
    Razonable RR
    Expert Opin Biol Ther; 2023; 23(7):619-631. PubMed ID: 37318043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic monoclonal antibodies for COVID-19 management: an update.
    Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
    Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients.
    Yetmar ZA; Bhaimia E; Razonable RR
    Curr Opin Organ Transplant; 2022 Aug; 27(4):269-276. PubMed ID: 36354253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review.
    Ravi G; Eerike M; Konda VR; Bisoi D; Raj GM; Priyadarshini R; Mali KR; Chaliserry LF
    Monoclon Antib Immunodiagn Immunother; 2023 Apr; 42(2):77-94. PubMed ID: 37129306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
    McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
    Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody therapies in the management of SARS-CoV-2 infection.
    Miguez-Rey E; Choi D; Kim S; Yoon S; Săndulescu O
    Expert Opin Investig Drugs; 2022 Jan; 31(1):41-58. PubMed ID: 35164631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.
    Gupta A; Konnova A; Smet M; Berkell M; Savoldi A; Morra M; Van Averbeke V; De Winter FH; Peserico D; Danese E; Hotterbeekx A; Righi E; ; De Nardo P; Tacconelli E; Malhotra-Kumar S; Kumar-Singh S
    J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36727404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
    Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
    J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.
    Owen C; Robinson S; Christofides A; Sehn LH
    Curr Oncol; 2022 May; 29(6):3940-3949. PubMed ID: 35735424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19.
    Zou J; Jing F
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies.
    Almagro JC; Mellado-Sánchez G; Pedraza-Escalona M; Pérez-Tapia SM
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for coronavirus disease 2019.
    Montastruc F; Lafaurie M; Flumian C; de Canecaude C
    Clin Microbiol Infect; 2023 Apr; 29(4):543.e1-543.e3. PubMed ID: 36464214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies.
    Leducq V; Zafilaza K; Fauchois A; Ghidaoui E; Sayon S; Dorival C; Meledje ML; Lusivika-Nzinga C; Yordanov Y; Martin-Blondel G; Carrat F; Marcelin AG; Soulie C
    J Infect Dis; 2024 May; 229(5):1341-1351. PubMed ID: 37996072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.